William Blair Estimates Nevro’s FY2026 Earnings (NYSE:NVRO)

Nevro Corp. (NYSE:NVRO) – Analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for Nevro in a research report issued on Tuesday, November 12th. William Blair analyst B. Vazquez anticipates that the medical equipment provider will post earnings of ($2.46) per share for the year. The consensus estimate for Nevro’s current full-year earnings is ($2.60) per share.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.40. Nevro had a negative return on equity of 23.35% and a negative net margin of 16.54%. The firm had revenue of $96.60 million during the quarter, compared to analyst estimates of $93.09 million. During the same quarter in the prior year, the firm posted ($0.65) earnings per share. The business’s quarterly revenue was down 7.0% compared to the same quarter last year.

A number of other research firms have also weighed in on NVRO. JPMorgan Chase & Co. lowered shares of Nevro from a “neutral” rating to an “underweight” rating in a report on Wednesday, August 7th. Citigroup dropped their price target on Nevro from $6.89 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, October 1st. Wolfe Research upgraded shares of Nevro from an “underperform” rating to a “peer perform” rating in a report on Thursday, August 8th. Robert W. Baird lifted their target price on shares of Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, JMP Securities reissued a “market perform” rating on shares of Nevro in a research note on Tuesday. Three research analysts have rated the stock with a sell rating and twelve have issued a hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $9.10.

Nevro Trading Down 4.9 %

Shares of NVRO opened at $5.06 on Wednesday. Nevro has a twelve month low of $4.38 and a twelve month high of $22.64. The company has a debt-to-equity ratio of 0.66, a current ratio of 4.77 and a quick ratio of 3.53. The firm has a fifty day simple moving average of $5.24 and a two-hundred day simple moving average of $7.48.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. State Board of Administration of Florida Retirement System boosted its stake in Nevro by 14.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,578 shares of the medical equipment provider’s stock valued at $167,000 after purchasing an additional 1,430 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Nevro by 5.0% during the second quarter. Rhumbline Advisers now owns 58,995 shares of the medical equipment provider’s stock valued at $497,000 after buying an additional 2,836 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Nevro by 1,788.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,932 shares of the medical equipment provider’s stock worth $58,000 after buying an additional 6,565 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in Nevro by 18.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 45,016 shares of the medical equipment provider’s stock worth $651,000 after buying an additional 7,004 shares during the last quarter. Finally, Blair William & Co. IL lifted its stake in Nevro by 13.9% during the 2nd quarter. Blair William & Co. IL now owns 59,404 shares of the medical equipment provider’s stock valued at $500,000 after acquiring an additional 7,250 shares during the period. Institutional investors own 95.52% of the company’s stock.

About Nevro

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.